International Care Bundle Evaluation in Cerebral Hemorrhage Research
Launched by REGION SKANE · May 20, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
The I-CATCHER trial is studying a new treatment approach for patients who experience spontaneous intracerebral hemorrhage (ICH), which is a type of stroke caused by bleeding in the brain. This trial will compare a structured treatment package, known as a Care Bundle, to the standard care typically provided. The goal is to see if this new treatment can lead to better health outcomes for patients within three months of their stroke. The Care Bundle includes early measures like lowering blood pressure and managing fever and high blood sugar, which have shown promise in previous studies.
To participate in the trial, individuals must be adults aged 18 or older and have been diagnosed with spontaneous ICH within 24 hours of their symptoms starting. However, certain people may not be eligible, such as those with specific severe health conditions or certain types of brain bleeding. While the trial is not yet recruiting participants, those who take part can expect to receive either the new treatment package or the usual care, and their progress will be closely monitored to assess the effectiveness of the new approach. This study is important as it aims to improve treatment for ICH patients in Sweden, Australia, and other high-income countries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (age ≥18 years)
- • Non-contrast computerized tomography (NCCT) imaging-verified diagnosis of spontaneous intracerebral haemorrhage
- • ≤24 hours from symptom onset or presumed symptom onset (last seen well)
- Exclusion Criteria:
- • Previous care limitation
- • End-stage comorbidity with short life-expectancy (\<6 m; e.g. terminal cancer)
- • ICH caused by brain tumor or cerebral venous thrombosis
- • Clinical signs of brain herniation at first presentation (unresponsive patient with bilaterally fixed, maximally dilated pupils)
- • Pregnant women beyond 22 weeks gestation may only be included after thorough discussion with an obstetrician to determine risks vs benefit.
About Region Skane
Region Skåne is a leading healthcare authority in Sweden, dedicated to advancing medical research and improving patient care through innovative clinical trials. Committed to fostering collaboration between researchers, healthcare professionals, and patients, Region Skåne aims to enhance the understanding of various health conditions and develop effective treatment strategies. With a focus on ethical standards and patient safety, the organization plays a pivotal role in shaping the future of healthcare in the region and beyond, ensuring that clinical trials are conducted with the highest level of scientific rigor and transparency.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ottawa, Ontario, Canada
Lund, , Sweden
Helsingborg, , Sweden
Umeå, , Sweden
Hässleholm, , Sweden
Karlskrona, , Sweden
Växjö, , Sweden
Kristianstad, , Sweden
Sundsvall, , Sweden
Ystad, , Sweden
Sydney, , Australia
Malmö, , Sweden
Lund, , Sweden
östersund, , Sweden
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported